Parameters to consider
| Parameters . | |
|---|---|
| Disease-related (parameters associated with poor prognosis) | • High ISS at relapse |
| • High-risk cytogenetics: t(4;14) del (17p) t(14.16) | |
| • Extramedullary disease | |
| • Short response to prior therapy | |
| • Aggressive relapse (rapid onset, hypercalcemia, renal failure) | |
| Patient-related | • Age |
| • Comorbidities | |
| • Performance status (ECOG) or frailty index | |
| Treatment-related | • Previous HDT/ASCT or not |
| • Previous bortezomib therapy or not bortezomib-naive or bortezomib-exposed | |
| • Previous lenalidomide therapy or not lenalidomide-naive or lenalidomide-exposed | |
| • Resistance to bortezomib/lenalidomide or not | |
| • Number of prior lines of treatment | |
| • Toxicity of prior treatments (myelotoxicity, peripheral neuropathy, thromboembolic event) | |
| • Mode of administration (oral vs IV or subcutaneous) | |
| Parameters . | |
|---|---|
| Disease-related (parameters associated with poor prognosis) | • High ISS at relapse |
| • High-risk cytogenetics: t(4;14) del (17p) t(14.16) | |
| • Extramedullary disease | |
| • Short response to prior therapy | |
| • Aggressive relapse (rapid onset, hypercalcemia, renal failure) | |
| Patient-related | • Age |
| • Comorbidities | |
| • Performance status (ECOG) or frailty index | |
| Treatment-related | • Previous HDT/ASCT or not |
| • Previous bortezomib therapy or not bortezomib-naive or bortezomib-exposed | |
| • Previous lenalidomide therapy or not lenalidomide-naive or lenalidomide-exposed | |
| • Resistance to bortezomib/lenalidomide or not | |
| • Number of prior lines of treatment | |
| • Toxicity of prior treatments (myelotoxicity, peripheral neuropathy, thromboembolic event) | |
| • Mode of administration (oral vs IV or subcutaneous) | |